Circulation

Tirzepatide improves outcomes in HFpEF with obesity

March 27, 2025

Tirzepatide improved health status, functional capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEf) and obesity while reducing heart failure events and medication burden. The findings position tirzepatide as a promising therapeutic option in this patient population.

Study details: The double-blind, randomized SUMMIT trial included 731 patients with HFpEF, class II-IV, and a BMI ≥30 kg/m². Participants, averaging 65 years of age (54% female; average BMI, 38.2), were assigned to tirzepatide (up to 15 mg weekly) or placebo for a median of 104 weeks. Patients had an average Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) of 53.5, a 6-minute walk distance of 303 meters, and 53% had experienced recent heart failure worsening.

Results: Tirzepatide significantly reduced the risk of cardiovascular death or worsening heart failure events (hazard ratios, 0.41-0.67). At 52 weeks, tirzepatide improved KCCQ-CSS by 6.9 points, 6-minute walk distance by 18.3 meters, and European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) health state index by 0.06. Patients also reported better overall health and required fewer heart failure medications.

Source:

Zile MR, et al; SUMMIT Trial Study Group. (2025, March 11). Circulation. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. https://pubmed.ncbi.nlm.nih.gov/39556714/